Digital technologies have presented a myriad of new solutions for improving cardiometabolic and behavioural health in the general population. However, the ways in which such advances could be applied to address the heightened health-risk behaviours and associated diseases in mental healthcare is unknown. To examine this, 492 young people with mental illness (YPMI) were recruited from 27 Primary Care and NHS mental healthcare sites across the UK, covering various diagnoses (excluding eating disorders). Participants were presented with four types of physical health apps, delivering: 1) Health Tracking; 2) Health Coaching; 3) Health Connections; and 4) Instructional Videos, and completed an online perspective-gathering exercise on the preferred utility, features, behavioural targets of these technologies, and barriers/facilitators to uptake. Results showed a high level of perceived utility across each of the four app types, with physical activity, sleep and diet emerging as preferred behavioural targets. Feedback on ideal app features indicated a need for integrated physical-mental health tracking, and expert-led instructional content/coaching, with less interest expressed towards sharing data with clinical teams. These findings can improve the development, future trials, and clinical implementation of digital lifestyle interventions in mental healthcare, through better accounting for the needs and preferences of YPMI.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1016/j.psychres.2024.116187 | DOI Listing |
BMC Res Notes
January 2025
Department of Otorhinolaryngology (ENT), School of Medicine, College of Medicine and Health Science, University of Gondar, Gondar, Ethiopia.
Background: Depressive symptom is the most common type of psychiatric co-morbidity among persons with epilepsy. Epilepsy patients are identified as at higher risk of suffering depressive symptom explicitly in low- and middle-income countries due to poor mental health care systems and financial burdens. The co-occurrence of depressive symptom among epilepsy patients deteriorates the prognosis of the disease and diminishes the quality of life of both the patients and their families.
View Article and Find Full Text PDFJ Pediatr Nurs
January 2025
Department of Medical Surgical Nursing, College of Nursing, University of Ha'il, Ha'il City, Saudi Arabia; Department of Nursing, Faculty of Medicine and Health Sciences, Hodeida University, Hodeida, Yemen.
Aim: This study aimed to evaluate the knowledge, attitudes, and acceptance of Electronic Health Records (EHRs) among nurses in Egypt.
Methods: A descriptive cross-sectional study was conducted involving 1217 nurses from 33 public and private hospitals. Data were collected using a self-administered online questionnaire, which assessed knowledge, attitudes, and acceptance of EHRs.
J Prev Alzheimers Dis
January 2025
Division of Neurogeriatrics, Department of Neurobiology, Care Sciences and Society, Karolinska Institutet, BioClinicum, 171 64 Solna, Sweden; Theme Inflammation and Aging, Karolinska University Hospital, 141 86 Stockholm, Sweden.
The advancement of disease-modifying treatments (DMTs) for Alzheimer's disease (AD), along with the approval of three amyloid-targeting therapies in the US and several other countries, represents a significant development in the treatment landscape, offering new hope for addressing this once untreatable chronic progressive disease. However, significant challenges persist that could impede the successful integration of this class of drugs into clinical practice. These challenges include determining patient eligibility, appropriate use of diagnostic tools and genetic testing in patient care pathways, effective detection and monitoring of side effects, and improving the healthcare system's readiness by engaging both primary care and dementia specialists.
View Article and Find Full Text PDFJ Prev Alzheimers Dis
January 2025
Barrow Neurological Institute, St. Joseph's Hospital and Medical Center, Phoenix, Arizona, USA. Electronic address:
Background: There are no approved oral disease-modifying treatments for Alzheimer's disease (AD).
Objectives: The objective of this study was to assess efficacy and safety of blarcamesine (ANAVEX®2-73), an orally available small-molecule activator of the sigma-1 receptor (SIGMAR1) in early AD through restoration of cellular homeostasis including autophagy enhancement.
Design: ANAVEX2-73-AD-004 was a randomized, double-blind, placebo-controlled, 48-week Phase IIb/III trial.
Spine J
January 2025
International Spine Study Group Foundation, Denver, Colorado, USA.
Background Context: Correcting sagittal malalignment in adult spinal deformity (ASD) is a challenging task, often requiring complex surgical interventions like pedicle subtraction osteotomies (PSOs). Different types of three-column osteotomies (3COs), including Schwab 3, Schwab 4, Schwab 4 with interbody cages, and the "sandwich" technique, aim to optimize alignment and fusion outcomes. The role of interbody cages in enhancing fusion and segmental correction remains unclear.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!